Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wegovy in Military Personnel with Obesity
NCT06468748Phase 4Withdrawn
- Sponsor
- U.S. Army Research Institute of Environmental Medicine
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in obesity, sponsored by U.S. Army Research Institute of Environmental Medicine. Primary endpoints: Weight Loss at 24 weeks, Body composition at 24 weeks and 1 more. Planned start Aug 2024; status: withdrawn.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06468748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468748.